In a year-end exploration of the biopharmaceutical landscape, this story delves into the contrasting approaches of large and small biopharma companies, addressing critical challenges and scrutinizing the role of Artificial Intelligence (AI) in drug development. With a focus on overcoming the “productivity paradox,” the narrative assesses the advantages and disadvantages of both large biopharmas and